Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Possible buy below $5? Any chance the VectivBio acquisition ends up not being as horrible as it currently appears? When might the acquired asset begin to generate revenue?
Hearing rumblings of IRWD this week. Anyone else?
Just In: $IRWD Ironwood Pharmaceuticals Inc (IRWD) Q3 2020 Earnings Call Transcript
Image source: The Motley Fool. Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Q3 2020 Earnings Call Nov 6, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Ironwood Pharmaceuticals Inc (IRWD) Q3 2020 Earnings Call Trans...
Find out more IRWD - Ironwood Pharmaceuticals Inc (IRWD) Q3 2020 Earnings Call Transcript
Just In: $IRWD Ironwood to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment
– Trial did not achieve statistically significant improvement in heartburn severity (primary endpoint) – – Ironwood plans to implement organizational restructuring, resulting in expected headcount reduction of approximately 100 full-time employees, or near...
In case you are interested IRWD - Ironwood to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment
News: $IRWD Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
– Phase IIIb study met all primary and secondary endpoints with statistical significance and demonstrated that linaclotide improved the overall abdominal symptoms of bloating, pain and discomfort in adults with IBS-C – – Results further support the efficacy and s...
Got this from https://marketwirenews.com/news-releases/ironwood-and-allergan-report-positive-topline-data-from-phase-iiib-trial-of-linzess-xae-linaclotide-in-adults-with-irritable-bowel-syndrome-with-constipation-ibs-c--8377600.html
* * $IRWD Video Chart 05-17-2019 * *
Link to Video - click here to watch the technical chart video
IRWD buy 11.365
https://www.ironwoodpharma.com/
normal chart
log chart
epilogue
SGYP down to 3 pennies after hours today
the signs were all there, but you had to be willing to read them.
if there is a list somewhere, like, "always go on the opposite end of the trade for all recommendations from these institutions" - most of the SGYP institutional investors should definitely be on it IMHO.
How did that work out for you;)
knew all too well what was going on behind the Synergy scenes;
http://www.nj.com/business/index.ssf/2012/08/bristol-myers_drug_flop_erases.html
if you make a multinational company lose a couple billion $ in short order & leave them stuck with trial deaths, AND expect anyone in the pharmaceutical industry ever to trust you again, you need to have your head examined imo. he's probably looking under his car every morning...
there's a really nice package deal available for you though from the experienced crew, if you're still game for it:
Synergy, $6 in January, now on sale at $1.90, Trovagene, went public at $24, now marked down to 51 cents for quick clearance, and ContraVir, $5 as recently as 2015, but now available for just 49 cents! Yes, you get all three of these made-to-be-sold companies for just $2.90! And, if you act now, we'll throw in 10 shares of Callisto Pharmaceuticals, a company which sank beneath the waves with Cap'n Gary at the helm!
Enjoy the front row seat to the final act of the drama, sure was expensive enough...
I did 10,000 shares on that one, didn't get in at the low, but out close to the top. Flipped it into sgyp in the low 3's
thanks for bringing it to my attention! that was nice, ~7.30s to $10.24 in less than a month, 30+% !
Hope you didn't miss it :) ?
you were right, we saw 7's this week. 52 week low
SGYP short volume 25 million plus now...looks like the hedgefunds are in the business to lose money then ?
under 10 coming your way soon. the trend is your friend
IRWD, 10.71 new 52 week low fact, not rant
8.00 in September lows
no pain data, skewed side effect profile = no partner IMO.
no partner = slim chance, if any, of competing in the marketplace for a primary care drug with an army of people promoting the first-to-market competitor, IMO.
simple as that.
rant all you want. doesn't change the fact that Phase III CIC data are out - and still no buyout & no partnership despite the "hey we're for sale" press article LOL.
that, and the low (~30%) institutional ownership of SGYP compared with IRWD (~100%), combined with the ~22 mill. short volume for SGYP speak volumes...
IRWD pennies of 51 week low, while market booms. Stock price heading in the same direction as the diarrhea it causes. despite misinformation by IRWD propagandist.. BTW, I bought a boatload of warrants at .36, now 4.00. I can be very patient for the next explosion. 2 phase 3 results and an NDA by year end
from an IRWD board? nice, just a little biased. Don't try to be naïve, you have no idea what is going on behind the scenes. and like I said you have lots of holders, but yahoo stats says 3 percent own over 5 percent, and that 3 percent includes insider holdings. Everyone owns a little. Cerrone TOOK 1/2 year with inhibitex, to get top buck, we have only been a month here. 4 catalysts by year end. we are up 165 percent, you? your short at 4 dollars is a FAILED trade
sooner or later the Wall Street hysteria, fanned by a couple of hyperbolic analyst op ed pieces, will be over; - the music will stop, people will wake up & valuations will adjust to reality. they always do.
I quote a comment of someone from "the trenches" posted on the IRWD CP board, who puts it in quite simple (& blunt) terms:
anonymous, Jul 22, 2015 at 9:37 AM
(quote) ...." Less diarrhea, yes but with that is less efficacy. You can't treat cic with no diarrhea and have the same efficacy. So you think you can hire a third of the reps ? So roughly 1 rep per state to grow the constipation market of 50 million? This is a primary care drug linzess has over 3000 people promoting it. When it is all said and done 80 percent of volume will come from pcp. You need a partner and despite your so called stellar efficacy and no side effects no one is stepping up. No pain data and skewed side effect data equals no partner. We developed plecanatide and linaclotide and kept linzess. I'm gonna go with the MIT scientists who discovered GCC on this one..."
http://www.cafepharma.com/boards/threads/we-should-buy-synergy.583049/
I don't know the answer, but do you think they are happy with the price DEpreciation, under 11, it has been YEARS since it has been that low
IRWD:
% of Shares Held by Institutional & Mutual Fund Owners: 110%
% of Float Held by Institutional & Mutual Fund Owners: 112%
Number of Institutions Holding Shares: 163
SGYP:
% of Shares Held by Institutional & Mutual Fund Owners: 29%
% of Float Held by Institutional & Mutual Fund Owners: 32%
Number of Institutions Holding Shares: 90
source: Yahoo finance 07/22/15
% of Shares Held by All Insider and 5% Owners: 2 percent. surprisingly low. lots with their toes in the water, but no ringing endorsements
I can explain the price drop in facts, but I can't help you to understand it
Chemist, you the only one here? Looks like it
but our price is going up, I am sorry, which way is this price going? It is not going to be long before our price eclipses yours
Sgyp new short volume ~ 22 mill; - go figure ??
chemist, short up to 17 mill, too bad you can't use your moniker to reformulate this drug into something better, but then again, what chemistry do you need to use a virus?
hot 6 page found in nature thing working for you? I am having trouble with my pixels, did wedbush lower the target to 11? that's lower than the current price
6/15 was days before the phase 3 results. I bet some more shorted the 9 down to 8 to cover the earlier bad trade. We hire 2 more big guns today, and the pump articles and increasing price targets are like ants around a popsicle on a picnic, they are everywhere. Synergy will do ma secondary at 13, pay back the loan, and actually lower their share count, and knock off the interest
yes, IRWD short interest up to ~16 million shares, but SGYP up even more to about ~21.5 million shares per 06/15 :
http://www.nasdaq.com/symbol/sgyp/short-interest
the hedge funds must be in the business to lose money, I guess...
Chemist, Last SI up 2 million, are there folks betting on this going down. are you hedged? Sgyp set to double
How about your long position here? 1/3 the diarrhea rate for plecanatide, and filing NDA in November. Has to severely stunt the growth here. What is the adage, the market is forward looking? However, maybe you can clarify. The guy who took IRWD through the NDA process, does he still work for you?
In a few months the ticker symbol for Synergy may not exist, in a perfect world